Warning: The NCBI web site requires JavaScript to function. more...
The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.
Herschkowitz JI, He X, Fan C, Perou CM.
Breast Cancer Res. 2008;10(5):R75. Epub 2008 Sep 9.
Related citations
Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer.
Bièche I, Lidereau R.
Mol Carcinog. 2000 Nov;29(3):151-8.
Proliferation-dependent expression and phosphorylation of pRB in B cell non-Hodgkin's lymphomas: dependence on RB1 copy number.
Galteland E, Smedshammer L, Suo Z, DeAngelis P, Stokke T.
Leukemia. 2002 Aug;16(8):1549-55.
Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer.
Silva J, Domínguez G, Silva JM, García JM, Gallego I, Corbacho C, Provencio M, España P, Bonilla F.
Oncogene. 2001 Jul 27;20(33):4586-90.
Expression of the retinoblastoma susceptibility gene in childhood rhabdomyosarcomas.
De Chiara A, T'Ang A, Triche TJ.
J Natl Cancer Inst. 1993 Jan 20;85(2):152-7.
A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer.
Cetani F, Pardi E, Viacava P, Pollina GD, Fanelli G, Picone A, Borsari S, Gazzerro E, Miccoli P, Berti P, Pinchera A, Marcocci C.
Clin Endocrinol (Oxf). 2004 Jan;60(1):99-106.
Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas.
Chi SG, deVere White RW, Muenzer JT, Gumerlock PH.
Clin Cancer Res. 1997 Oct;3(10):1889-97.
Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13.
Cleton-Jansen AM, Collins N, Lakhani SR, Weissenbach J, Devilee P, Cornelisse CJ, Stratton MR.
Br J Cancer. 1995 Nov;72(5):1241-4.
A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.
Breast Cancer Res. 2008;10(5):R88. Epub 2008 Oct 17.
The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours.
Varley JM, Armour J, Swallow JE, Jeffreys AJ, Ponder BA, T'Ang A, Fung YK, Brammar WJ, Walker RA.
Oncogene. 1989 Jun;4(6):725-9. Erratum in: Oncogene 1990 Feb;5(2):245.
Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms.
Silva J, Silva JM, Domínguez G, García JM, Cantos B, Rodríguez R, Larrondo FJ, Provencio M, España P, Bonilla F.
J Pathol. 2003 Mar;199(3):289-97.
Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
Sørlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Børresen-Dale AL.
BMC Genomics. 2006 May 26;7:127.
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, Minna JD, Pollack JR.
PLoS One. 2009 Jul 3;4(7):e6146.
Loss of heterozygosity associated with uniparental disomy in breast carcinoma.
Murthy SK, DiFrancesco LM, Ogilvie RT, Demetrick DJ.
Mod Pathol. 2002 Dec;15(12):1241-50.
Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J, Bektas N, Hartmann A, Kristiansen G, Heindrichs U, Knüchel R, Dahl E.
Breast Cancer Res. 2008;10(5):R82. Epub 2008 Sep 30.
Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.
Lundgren K, Holm K, Nordenskjöld B, Borg A, Landberg G.
Breast Cancer Res. 2008;10(5):R81. Epub 2008 Sep 29.
Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer.
Chatterjee SJ, George B, Goebell PJ, Alavi-Tafreshi M, Shi SR, Fung YK, Jones PA, Cordon-Cardo C, Datar RH, Cote RJ.
J Pathol. 2004 Jul;203(3):762-70.
Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers.
Yu E, Ahn YS, Jang SJ, Kim MJ, Yoon HS, Gong G, Choi J.
Breast Cancer Res Treat. 2007 Mar;101(3):269-78. Epub 2006 Aug 9.
Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data.
Grigoriadis A, Mackay A, Reis-Filho JS, Steele D, Iseli C, Stevenson BJ, Jongeneel CV, Valgeirsson H, Fenwick K, Iravani M, Leao M, Simpson AJ, Strausberg RL, Jat PS, Ashworth A, Neville AM, O'Hare MJ.
Breast Cancer Res. 2006;8(5):R56.
[Prognostic and predictive impact of protein expression profiling in high risk breast cancer patients treated with high-dose chemotherapy].
Diallo-Danebrock R, Ting E, Gluz O, Herr A, Mohrmann S, Geddert H, Gabbert HE, Nitz U, Poremba C.
Verh Dtsch Ges Pathol. 2007;91:187-96. German.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on